Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 28Nivolumab 13Carboplatin 9fludarabine 7Paclitaxel 7Gemcitabine 7Docetaxel 7Cyclophosphamide 7Cisplatin 7Trastuzumab 5palbociclib 4cemiplimab 4avelumab 4atezolizumab 4Ipilimumab 4Fluorouracil 4Filgrastim 4Drug Therapy 4Cetuximab 4fludarabine phosphate 3epacadostat 3durvalumab 3Taxes 3Oxaliplatin 3Fulvestrant 3zimberelimab 2ulixertinib 2trametinib 2tisotumab vedotin 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Imlunestrant × Head & Neck × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡